{"id":"cyclobutyrol","rwe":[{"pmid":"2310370","year":"1990","title":"Inhibitory action of cyclobutyrol on the secretion of biliary cholesterol and phospholipids.","finding":"","journal":"The Biochemical journal","studyType":"Clinical Study"},{"pmid":"2360911","year":"1990","title":"Choleretic mechanism and effects of cyclobutyrol in the rat: dose-response relationship.","finding":"","journal":"Biomedica biochimica acta","studyType":"Clinical Study"},{"pmid":"2574569","year":"1989","title":"Inhibition of biliary cholesterol and phospholipid secretion during cyclobutyrol-induced hydrocholeresis.","finding":"","journal":"The Biochemical journal","studyType":"Clinical Study"},{"pmid":"14205635","year":"1964","title":"[A NEW MEDICATION FOR DIGESTIVE DISORDERS OF HEPATO-BILIARY ORIGIN: COMBINATION OF SODIUM CYCLOBUTYROL, SORBITOL AND ATROPINE SULFATE].","finding":"","journal":"Journal de medecine de Lyon","studyType":"Clinical Study"}],"tags":[{"label":"cyclobutyrol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A05AX03","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"1-hydroxy-alpha-ethylcyclohexylacetic acid","offLabel":[],"synonyms":["cyclobutyrol sodium","sodium cyclobutyrate","cyclobutyrol","1-Hydroxy-alpha-ethylcyclohexylacetic acid"],"timeline":[],"approvals":[],"brandName":"1-Hydroxy-Alpha-Ethylcyclohexylacetic Acid","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"cyclobutyrol","explanation":"Imagine your body's cells are like locks, and the key to unlocking them is a specific shape that fits perfectly. Cyclobutyrol is like a key that tries to fit into one of these locks, but we don't yet know which lock it's meant for or how it will affect the cell's behavior.","oneSentence":"Cyclobutyrol is thought to work by interacting with a specific molecular target, although the exact mechanism is not yet fully understood.","technicalDetail":"Cyclobutyrol is a small molecule that binds to a specific protein or receptor, potentially altering its activity or expression, although the precise molecular details of this interaction are currently unknown."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/752","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CYCLOBUTYROL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:21:37.839882","biosimilars":[],"competitors":[{"drugName":"maralixibat hydrochloride","drugSlug":"maralixibat-hydrochloride","fdaApproval":"2021-09-29","relationship":"same-class"},{"drugName":"odevixibat","drugSlug":"odevixibat","fdaApproval":"2021-07-20","patentExpiry":"Nov 8, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"cyclobutyrol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"maralixibat-hydrochloride","brandName":"maralixibat hydrochloride","genericName":"maralixibat hydrochloride","approvalYear":"2021","relationship":"same-class"},{"drugId":"odevixibat","brandName":"odevixibat","genericName":"odevixibat","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005318","UNII":"8T4L120N6M","CHEBI":"CHEBI:61024","INN_ID":"1149","RXNORM":"21954","UMLSCUI":"C0056739","ChEMBL_ID":"CHEMBL1697739","KEGG_DRUG":"D07104","DRUGBANK_ID":"DB13493","PUBCHEM_CID":"72065","SECONDARY_CAS_RN":"1130-23-0","MESH_SUPPLEMENTAL_RECORD_UI":"C001383"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":4,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"A05AX03","allCodes":["A05AX03"]},"biosimilarFilings":[],"recentPublications":[{"date":"1990 Feb 15","pmid":"2310370","title":"Inhibitory action of cyclobutyrol on the secretion of biliary cholesterol and phospholipids.","journal":"The Biochemical journal"},{"date":"1990","pmid":"2360911","title":"Choleretic mechanism and effects of cyclobutyrol in the rat: dose-response relationship.","journal":"Biomedica biochimica acta"},{"date":"1989 Oct 15","pmid":"2574569","title":"Inhibition of biliary cholesterol and phospholipid secretion during cyclobutyrol-induced hydrocholeresis.","journal":"The Biochemical journal"},{"date":"1964 Oct 5","pmid":"14205635","title":"[A NEW MEDICATION FOR DIGESTIVE DISORDERS OF HEPATO-BILIARY ORIGIN: COMBINATION OF SODIUM CYCLOBUTYROL, SORBITOL AND ATROPINE SULFATE].","journal":"Journal de medecine de Lyon"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"1-Hydroxy-Alpha-Ethylcyclohexylacetic Acid, also known as Cyclobutyrol, is a small molecule drug in the cyclobutyrol class. Its mechanism of action and target are currently unknown, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its commercial status, pharmacokinetics, or safety profile. Further research is needed to fully understand the potential benefits and risks of this compound. Due to its lack of FDA approval and limited information, Cyclobutyrol is not currently available as a prescription medication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}